Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock

Martine A. Rothblatt, the Chairperson and CEO of United Therapeutics Corp, exercised stock options and later sold shares, amounting to around $5.54 million. This occurred on October 22, 2026, under a pre-set 10b5-1 trading plan since November 7, 2025. On that date, she bought 9,500 shares at $117.76 each, totaling $1,118,720. The company's stock was traded near its 52-week high of $609.35, up over 40% in the past year.

Rothblatt's shares were held indirectly through a family trust. Post the sale, she held 324,603 shares indirectly via this trust. United Therapeutics recently reported a revenue miss in Q2, leading to a price target reduction by BofA Securities. However, legal victories, including a settlement with Liquidia Technologies for $380.7 million, and patent rulings have led to price targets being raised by firms like Jefferies and Cantor Fitzgerald, setting them at $728.

BTIG upgraded the company to Buy with a price target of $728, citing a significant legal win. However, Goldman Sachs initiated coverage with a Sell rating and a price target of $321, highlighting issues with the company’s trading metrics and declining base business.